Get the Stockscreener App
0.8499
8.61%
0.0674
Estrella Immunopharma Inc stock is traded at $0.8499, with a volume of 2,146.
It is up +8.61% in the last 24 hours and down -26.10% over the past month.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
See More
Previous Close:
$0.7825
Open:
$0.8509
24h Volume:
2,146
Relative Volume:
0.02
Market Cap:
$28.32M
Revenue:
-
Net Income/Loss:
$-8.53M
P/E Ratio:
-7.289
EPS:
-0.1166
Net Cash Flow:
$-12.75M
1W Performance:
-5.05%
1M Performance:
-26.10%
6M Performance:
-15.01%
1Y Performance:
-44.45%
1-Day Range:
$0.80
$0.9199
1-Week Range:
$0.63
$0.95
52-Week Range:
$0.63
$3.23
Estrella Immunopharma Inc Stock (ESLA) Company Profile
Name
Estrella Immunopharma Inc
Sector
Industry
Phone
(510) 318-9098
Address
5858 HORTON STREET, SUITE 370, EMERYVILLE
Estrella Immunopharma Inc Stock (ESLA) Latest News
First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas - CGTLive™
Estrella Immunopharma Inc (ESLA) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Stocks to Watch: Wynn Resorts, Estrella Immunopharma, Amazon.com - MarketWatch
Stocks to Watch : Wynn Resorts, Estrella Immunopharma, Amazon.com - Marketscreener.com
BeyondSpring (BYSI) Stock Surges 6.83% Amid High Volume Trading - GuruFocus.com
Estrella Immunopharma Shares Rise on Lymphoma Patient's Treatment Response - MarketWatch
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS - Business Wire
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
EXTR INVESTOR UPDATE: Suffer Losses on Your Extreme Networks, Inc. Investment? Contact BFA Law by October 15 about Pending Class Action Lawsuit (Nasdaq:EXTR) - ForexTV.com
Arizona State Retirement System Has $78,000 Stock Holdings in Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) - Defense World
Shareholders that lost money on Extreme Networks, Inc. (EXTR) Urged to Join Class Action – Contact The Gross Law Firm to Learn More - ForexTV.com
Elutia Inc. (NASDAQ:ELUT) Sees Large Decrease in Short Interest - Defense World
Kessler Topaz Meltzer & Check, LLP Reminds Investors of - GlobeNewswire
Extra Storage rises on Jefferies upgrade - XM
Debt-Free Multibagger Stock Hit 18 Consecutive Upper Circuits & 52-Week Highs: Will the Rally Come to a Halt? - Dalal Street Investment Journal
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Extreme Networks, Inc.EXTR - PR Newswire
Extreme Networks (EXTR) Tumbled 18% After Guiding For - GlobeNewswire
Clene (NASDAQ:CLNN) Stock Quotes, Forecast and News Summary - Benzinga
The Psychology of Extreme Networks Inc. Inc. (EXTR) Price Performance: Understanding Market Sentiment - The InvestChronicle
Estrella Immunopharma Welcomes New Chairperson, Expands Board - TipRanks
Uptake of Nononcology Gene Therapy Remains Slow in Hematology - CGTLive™
Estrella Immunopharma appoints new chairperson to board - Investing.com India
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member - 01Net
ESLAWEstrella Immunopharma, Inc. Warrant Latest Stock News & Market Updates - StockTitan
Estrella Immunopharma, Inc. (NASDAQ:ESLA) Sees Large Growth in Short Interest - MarketBeat
Wall Street today: US stocks trade higher after promising inflation data raises Fed rate cut bets; 3M Co. gains 18.99% - MSN
Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas Doses First Patient - CGTLive™
Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Up 8.5% in July - MarketBeat
ESLA’s Stock Tango: The Dance of Gains and Losses in 2023 - The InvestChronicle
Wall Street today: US stocks trade higher after promising inflation data raises Fed rate cut bets; 3M Co. gains 18.99% | Stock Market News - Mint
Keppel REIT (OTCMKTS:KREVF) Sees Large Growth in Short Interest - American Banking and Market News
Apple Inc. (NASDAQ:AAPL) Shares Acquired by Saxon Interests Inc. - American Banking and Market News
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Up 24.9% in June - American Banking and Market News
Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Up 60.0% in June - MarketBeat
Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update - Defense World
Around the Helix: Cell and Gene Therapy Company Updates – July 10, 2024 - CGTLive™
Estrella Immunopharma streamlines operations with subsidiary merger By Investing.com - Investing.com India
ZUU Co. Ltd. executives purchase Pono Capital two shares worth $390 By Investing.com - Investing.com
Maersk exits DB Schenker bid; Citi reaffirms sell rating on stock By Investing.com - Investing.com
Entergy appoints new directors across subsidiaries By Investing.com - Investing.com UK
AEON Biopharma (AMEX:AEON) Stock Quotes, Forecast and News Summary - Benzinga
Halliburton (NYSE:HAL) Receives Average Rating of “Buy” from Analysts - Defense World
iBio, Inc. (NYSEAMERICAN:IBIO) Sees Significant Growth in Short Interest - Defense World
Estrella Immunopharma, Inc. (NASDAQ:ESLA) Sees Significant Growth in Short Interest - Defense World
Head-To-Head Survey: Mynd.ai (OTCMKTS:MYND) & New Oriental Education & Technology Group (NYSE:EDU) - Defense World
We Think Estrella Immunopharma (NASDAQ:ESLA) Can Afford To Drive Business Growth - Yahoo Movies UK
Omid Hamid, MD, on Clinic Experience With TIL vs CAR-T Therapy Administration - CGTLive™
Ratio Analysis: Unpacking Estrella Immunopharma Inc (ESLA)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
The Honest Company, Inc. (NASDAQ:HNST) Sees Significant Decline in Short Interest - Defense World
LakeShore Biopharma (NASDAQ:LSB) Stock Quotes, Forecast and News Summary - Benzinga
ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024 - InvestorPlace
Estrella Immunopharma Inc Stock (ESLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):